Hyperemesis gravidarum: current concepts and management

N K Kusçu, F Koyuncu

Hyperemesis gravidarum is a common problem for an obstetrician. Though nausea and vomiting are quite common in pregnancy, hyperemesis is found in only 1–20 patients per 1000. In this practical review, a general outline of the syndrome, its relation to the gastrointestinal system and thyroid, mild and rare severe complications, and conventional treatment versus newer options are discussed.

Hyperemesis gravidarum is defined as vomiting in pregnancy that is sufficiently persistent to produce weight loss, dehydration, acidosis from starvation, alkalosis from loss of hydrochloric acid in vomitus, and hypokalaemia. All these symptoms are not absolutely necessary for the diagnosis. Mild to moderate ketonuria may be seen in urinary analysis. High or rapidly rising steroids seem to play a part in aetiology, and raised liver enzymes are seen in 15%–25% of women who are hospitalised. Enzyme levels are not usually increased more than four times the upper normal limit. Risk factors vary among different populations and female sex of the offspring, several previous pregnancies, and a high daily intake of primarily saturated fat before pregnancy are reported to cause a higher risk.

Besides these factors, gestational trophoblastic disease, multiple pregnancy, and psychology of the patient are other major concerns. Serum amylase levels have been reported to rise in some of the patients with hyperemesis gravidarum, and this amylase comes from the salivary gland not from the pancreas. Immunological factors such as immune globulins, C3, C4, and lymphocyte counts were found to be significantly higher in hyperemesis gravidarum, which may suggest a role for immunological activity in pregnancy. If thyrotoxicosis accompanies hyperemesis, mean serum β-human chorionic gonadotrophin (hCG), IgG, and IgM concentrations rise to a higher extent. These factors may exaggerate the stimulatory effect of β-hCG. In addition, a positive relationship between hyperemesis and maternal serum prostaglandin E2 concentrations was detected.

Gastric emptying and intestinal transit times may be delayed in pregnancy because of hormonal or mechanical factors. But, on the contrary, gastric emptying of solids was reported not to change during pregnancy; however, in patients recovering from hyperemesis gravidarum, solid emptying time was found to increase, correlating with abnormal thyroid hormones.

The role of serotonin (5-hydroxytryptamine) was investigated, but no association between increased serotonin secretion and hyperemesis gravidarum was found. However, several serotonin receptor subtypes have been shown to be related to emesis. Helicobacter pylori infection is reported to be associated with hyperemesis gravidarum. Serum IgG concentrations raised against H pylori are higher in patients with hyperemesis gravidarum when compared with asymptomatic pregnant women. Two patients with severe hyperemesis gravidarum responded dramatically to oral erythromycin therapy, which they were taking for other non-related conditions, and who were later found to be seropositive for H pylori. Three other patients refractory to standard medical therapy were given antibiotics and a proton pump inhibitor or H2 receptor antagonist and hyperemesis resolved. Persistent nausea and vomiting beyond the second trimester should raise suspicions of an active peptic ulcer caused by H pylori.

HYPEREMESIS GRAVIDARUM AND THE THYROID

Thyroid function changes with the onset of pregnancy: thyroxine binding globulin, total triiodothyronine and thyroxine concentrations, thyroglobulin, and renal iodide clearance all increase. Also hCG has mild thyroid stimulating activity. Transient hyperthyroidism is seen in about 60% of patients with hyperemesis gravidarum. The increase in thyroid hormones is attributable to either higher hCG concentrations, or hCG hypersensitive thyrotrphin receptors in an overactive thyroid, or probable secretion of a variant of hCG with increased thyroid stimulating activity.

Patients with transient hyperthyroidism have no previous thyroid illness, goitre is usually absent, and thyroid antibodies are negative. These patients are more likely to have abnormal liver function tests and electrolytes. The more severe the vomiting the greater degree of thyroid stimulation and the higher the concentration of hCG. Transient hyperthyroidism may be responsible for 40%–70% of thyroid function abnormalities in pregnancy and usually resolves by 18 weeks without treatment and sequelae. Only a small proportion of these patients have clinical thyrotoxicosis and maybe these are the patients who secrete a more potent molecular variant of hCG.

Besides hyperemesis gravidarum occurring during the first pregnancy, recurrence in two
consecutive pregnancies has been reported. Hyperemesis gravidarum was seen in three consecutive pregnancies and transient hyperthyroidism was diagnosed in two of them. A modified variant of hCG was considered to play a part in this recurrence.

COMPLICATIONS OF HYPEREMESIS GRAVIDARUM
Both relatively benign and pernicious complications may be caused by hyperemesis gravidarum. Weight loss, dehydration, acidosis from malnutrition, alkalosis from vomiting, hypokalaemia, muscle weakness, electrocardiographic abnormalities, tetany, and psychological disturbances may be included in the “benign” group. Life threatening complications include oesophageal rupture due to severe vomiting, Wernicke's encephalopathy, central pontine myelinolysis, retinal haemorrhage, renal damage, spontaneous pneumomediastinum, intrauterine growth retardation, and fetal death. A patient with hyperemesis gravidarum has been reported to have had epistaxis at the 15th week of gestation because of an inadequate intake of vitamin K caused by severe emesis and her inability to tolerate solids and fluids. With replacement of vitamin K, coagulation parameters returned to normal and the disorder resolved. Vasospasm of cerebral arteries associated with hyperemesis gravidarum was reported in two patients. The vasospasm was diagnosed by magnetic resonance imaging angiography and the patients responded to fluid and electrolyte replacement.

MANAGEMENT OF HYPEREMESIS GRAVIDARUM
Appropriate parenteral fluid and electrolyte replacement is the initial treatment regimen for hyperemesis gravidarum. Various antiemetics may be given with vitamin supplementation. Promethazine, prochlorperazine, chlorpromazine, meclizine, droperidol-diphenhydramine, and metoclopramide are commonly used agents to alleviate nausea and vomiting. The intravenous or rectal route can be used initially and changed to the oral route when the symptoms begin to subside. If no response is observed within several days and the symptoms persist to an even higher degree, gastroenteritis, cholecystitis, pancreatitis, hepatitis, peptic ulcer, pylonephritis, and the fatty liver of pregnancy must be included in the differential diagnosis and the patient must be evaluated in this order. Psychological support from both the medical team and the patient’s family is an additive to the management. The patient must avoid foul smells and undesired foods as both may trigger vomiting. After discharge from hospital the syndrome recurs in some patients and readmission and rehospitalisation may be necessary. Besides antiemetic medications, pyridoxine appears to be more effective in reducing the severity of nausea. Adrenocorticotropic hormone had no benefit, but ginger was found to diminish or eliminate the symptoms of hyperemesis gravidarum without any side effects. The mutagenic effects of ginger are not known in humans.

Newer drugs
Continuous droperidol infusion and bolus intravenous diphenhydramine were studied in hyperemesis gravidarum and compared with other patients who did not receive any of the drugs. The study group had a shorter stay in hospital with fewer readmissions. Droperidol-diphenhydramine treatment was reported to be both beneficial and cost effective.

Ondansetron is a 5-hydroxytryptamine receptor antagonist which is used to prevent severe nausea and vomiting during chemotherapy and in the postoperative period. It is listed as a category B drug but is usually avoided during the first trimester. Though serotonin is not implicated in the pathogenesis of hyperemesis gravidarum, ondansetron may be reserved for refractory cases. No adverse effect for either the mother or the fetus was seen in one patient who was treated with the drug intermittently in every trimester. On the contrary, no benefit over promethazine has been reported when the two drugs were compared in a double blinded fashion including 15 patients in each group. No difference in the relief of nausea, weight gain, and days of hospitalisation was seen.

Steroids may be used as an alternative regimen in patients refractory to standard therapy. It was first reported in 1953 that cortisone treatment led to complete cessation of hyperemesis. Since then, various forms of therapy have been used. A short course of methylprednisolone, 16 mg three times daily, tapering the dose during the course of two weeks was found to be more effective when compared with promethazine. There was a significant difference rate in readmission of patients. Birth weight and Apgar scores did not differ. The drug is thought to exert its effect through the chemoreceptor trigger zone located in the brain stem. This mode of therapy could be begun in the hospital and continued in an outpatient setting and reserved for patients refractory to standard intravenous hydration and antiemetics. In another study intravenous hydrocortisone was followed with oral prednisolone in seven patients with intractable hyperemesis gravidarum. Vomiting stopped within three hours of the first dose of hydrocortisone and the symptoms resolved within days with the resumption of normal eating, reversal of muscle wasting, and regain of lost weight.

Parenteral nutrition may be necessary in severe cases. Enteral feeding is an alternative approach after acute symptoms subside with initial therapy. This form of nutrition should be considered in patients who cannot tolerate oral feeding despite antiemetic treatment. Sometimes it is quite difficult for a patient to eat with the burden of severe nausea and vomiting. Hsu et al used a nasogastric feeding tube in seven women with intractable vomiting for nutritional supplementation; this was found to be effective in relieving the symptoms of hyperemesis gravidarum.

Maternal and fetal outcomes of hyperemesis gravidarum were investigated in two different studies involving 193 and 138 patients respectively. Of 193 patients, 24% required hospitalisation and one patient required parenteral nutrition. Birth weight, gestational age, preterm delivery, Apgar scores, perinatal mortality, and incidence of fetal anomalies did not differ between hyperemetic patients and the general population. In the other study, no increased risk of growth retardation, congenital anomalies, and prematurity was detected.

In conclusion, vomiting and/or nausea are common during pregnancy but hyperemesis gravidarum occurs in 1–20 patients per 1000. Most patients require hospitalisation and antiemetics and even short term steroid therapy. Series complications are rare but medical therapy is mandatory. Hyperthyroidism may be found in about 60% of patients, but may not require specific therapy. H pylori infection must be considered in intractable cases and appropriate antibiotics should be given. Enteral feeding is an alternative therapy for refractory cases.
QUESTIONS (ANSWERS ON NEXT PAGE)

1. What is the incidence of hyperemesis gravidarum (per 1000 pregnant patients)?
   (A) 10
   (B) 25
   (C) 35
   (D) 50
   (E) 100

2. Which one of the following statements about hyperemesis gravidarum is false?
   (A) Acidosis occurs due to negative energy balance.
   (B) Ketouria is not the sine qua non of the syndrome.
   (C) Nausea is accepted to be the result of high steroid levels.
   (D) Raised liver enzymes may be seen in severe cases.
   (E) Perinatal morbidity and mortality rates are high in hyperemetic patients.

3. What is the mechanism of hyperthyroidism seen in patients with hyperemesis gravidarum?
   (A) hCG may stimulate the thyroid.
   (B) Thyrotrophin receptors may be more sensitive to hCG.
   (C) Both.
   (D) None.

4. Which treatment is used for hyperemesis gravidarum in patients with hyperemesis gravidarum?
   (A) Propylthiouracil.
   (B) Methimazole.
   (C) Propranolol.
   (D) Surgery.
   (E) None.

5. Which one of the following statements is false about treatment of the syndrome?
   (A) Antihistamines are usually the initial step for management of the syndrome, and they are safe to use during the first trimester.
   (B) Short term steroid therapy may be given to intractable cases.
   (C) Ondansetron may be superior to antihistamines.
   (D) Total parenteral nutrition should be given in severe form.
   (E) Psychological support is very important and should be given by both the family of the patient and the medical team.

Key references


Authors’ affiliations

N K Kuscu, F Koyuncu, Celal Bayar University, School of Medicine, Department of Obstetrics and Gynaecology, Manisa, Turkey

REFERENCES


ANSWERS
1. A; 2. E; 3. C; 4. E; 5. C.
Hyperemesis gravidarum: current concepts and management

N K Kuscu and F Koyuncu

Postgrad Med J 2002 78: 76-79
doi: 10.1136/pmj.78.916.76

Updated information and services can be found at:
http://pmj.bmj.com/content/78/916/76

These include:

References
This article cites 44 articles, 3 of which you can access for free at:
http://pmj.bmj.com/content/78/916/76#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/